An update on carbapenem resistance in nonfermenting gram-negative bacteria

KV Sreejith, B Arun, VK Anjana, K Sumesh, MohindC Mohan
{"title":"An update on carbapenem resistance in nonfermenting gram-negative bacteria","authors":"KV Sreejith, B Arun, VK Anjana, K Sumesh, MohindC Mohan","doi":"10.4103/amhs.amhs_87_23","DOIUrl":null,"url":null,"abstract":"Antimicrobial resistance is considered one of the most important and severe global public health threats. Carbapenems are the drug of choice that can be employed in treating severe bacterial infections and emergency scenarios caused by multidrug-resistant infections. In the present situation, resistance to carbapenem has emerged as a significant global public health problem due to its complications in hospitalized settings. Carbapenems were once considered the backbone of treating life-threatening infections, but with the emergence of resistance, their utility as a life-saving drug has been compromised. The nonfermenting Gram-negative bacteria (NFGNB) are a group of organisms with the potential to cause difficulties in treating life-threatening infections, often in the cases of immunocompromised patients with multiple preexisting comorbidities. Most of the members in this group are intrinsically resistant to multiple antibiotics and carbapenems are the drug of choice for such infections. However, the rate of carbapenem resistance in NFGNB is gradually increasing worldwide and the need to study the mechanism of carbapenem resistance in nonfermenting Gram-negative bacilli is very important in the combat against multidrug-resistant infections. This review emphasizes the characteristics of the NFGNB, their clinical impact, detection of resistance, and the other applicable treatment strategies.","PeriodicalId":8296,"journal":{"name":"Archives of Medicine and Health Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medicine and Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/amhs.amhs_87_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Antimicrobial resistance is considered one of the most important and severe global public health threats. Carbapenems are the drug of choice that can be employed in treating severe bacterial infections and emergency scenarios caused by multidrug-resistant infections. In the present situation, resistance to carbapenem has emerged as a significant global public health problem due to its complications in hospitalized settings. Carbapenems were once considered the backbone of treating life-threatening infections, but with the emergence of resistance, their utility as a life-saving drug has been compromised. The nonfermenting Gram-negative bacteria (NFGNB) are a group of organisms with the potential to cause difficulties in treating life-threatening infections, often in the cases of immunocompromised patients with multiple preexisting comorbidities. Most of the members in this group are intrinsically resistant to multiple antibiotics and carbapenems are the drug of choice for such infections. However, the rate of carbapenem resistance in NFGNB is gradually increasing worldwide and the need to study the mechanism of carbapenem resistance in nonfermenting Gram-negative bacilli is very important in the combat against multidrug-resistant infections. This review emphasizes the characteristics of the NFGNB, their clinical impact, detection of resistance, and the other applicable treatment strategies.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非发酵革兰氏阴性菌碳青霉烯类耐药研究进展
抗菌素耐药性被认为是最重要和最严重的全球公共卫生威胁之一。碳青霉烯类药物可用于治疗严重细菌感染和多重耐药感染引起的紧急情况。在目前的情况下,碳青霉烯耐药已成为一个重大的全球公共卫生问题,由于其并发症在住院环境。碳青霉烯类曾被认为是治疗危及生命的感染的支柱,但随着耐药性的出现,它们作为救命药物的效用受到了损害。非发酵革兰氏阴性菌(NFGNB)是一组可能对治疗危及生命的感染造成困难的微生物,通常在免疫功能低下且已有多种合并症的患者中。该组中的大多数成员本质上对多种抗生素具有耐药性,碳青霉烯类药物是此类感染的首选药物。然而,在世界范围内,NFGNB对碳青霉烯类药物的耐药率正在逐渐上升,研究非发酵革兰氏阴性杆菌对碳青霉烯类药物的耐药机制对对抗多重耐药感染具有重要意义。本文综述了NFGNB的特点、临床影响、耐药检测以及其他适用的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
25 weeks
期刊最新文献
Blood Donor Selection Profile an Important Tool for Blood Safety: An Institutional Experience Choosing the Right Angiotensin Converting Enzyme Inhibitors; Gender –Specific Approach A Rare Case of Dentigerous Cyst in a 1-day-old Neonate Carotid Cavernous Fistula – Radiological Features A Retrospective Study on Maternal and Neonatal Outcomes of Adolescent Pregnancies at a Referral Hospital in Bengaluru
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1